- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01634321
The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty
August 1, 2014 updated by: Daewoong Pharmaceutical Co. LTD.
The Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty; A Single, Open, Multi-center, Prospective Study
The purpose of this Clinical Trial was to Evaluate the Efficacy and Safety of Luphere Depot Inj.
3.75mg(Leuprolide acetate 3.75mg) in patients with precocious puberty.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
63
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Soo-won, Korea, Republic of
- Ajou University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 9 years (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 4~8 years & tanner stage ≥ 2
Exclusion Criteria:
- Previous treatment with GnRH analog therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Luphere
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
At 24 weeks, percentage of subjects with suppression of peak-stimulated Luteinizing Hormone (LH) concentrations
Time Frame: At 24 weeks
|
At 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2011
Primary Completion (ACTUAL)
August 1, 2012
Study Completion (ACTUAL)
August 1, 2012
Study Registration Dates
First Submitted
July 3, 2012
First Submitted That Met QC Criteria
July 5, 2012
First Posted (ESTIMATE)
July 6, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
August 4, 2014
Last Update Submitted That Met QC Criteria
August 1, 2014
Last Verified
August 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DW_LP1M002P
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Central Precocious Puberty
-
AbbVieCompletedCentral Precocious Puberty (CPP)United States, Puerto Rico
-
Daewoong Pharmaceutical Co. LTD.Recruiting
-
Endo PharmaceuticalsCompletedCentral Precocious Puberty
-
Tolmar Inc.CompletedPrecocious Puberty, CentralUnited States, Canada, Argentina, Chile, Mexico, New Zealand
-
University of MinnesotaEndo Pharmaceuticals; Atlantic Center for Research; Goryeb Children's HospitalTerminatedCentral Precocious PubertyUnited States
-
Debiopharm International SARecruiting
-
Foresee Pharmaceuticals Co., Ltd.QPS Holdings LLC; Changchun GeneScience Pharmaceutical Co., Ltd.RecruitingPuberty; Precocious, CentralUnited States, China, Taiwan, Puerto Rico
-
IpsenCompleted
-
TakedaCompletedCentral Precocious PubertyChina
-
TakedaCompletedCentral Precocious PubertyChina
Clinical Trials on Luphere depot 3.75mg(Leuprolide acetate 3.75mg)
-
Peptron, Inc.Not yet recruiting
-
University of Colorado, DenverEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
IpsenCompletedDeep Infiltrating Endometriosis (DIE)China
-
AbbottFraktal.com.pl; Med-net.plCompletedLower Urinary Tract Symptoms | Advanced Prostate CancerPoland, Ukraine
-
National Taiwan University HospitalDebiopharm International SA; Ministry of Health and WelfareNot yet recruitingTriple Negative Breast Cancer | Premenopausal Breast Cancer
-
TakedaRecruitingCentral Precocious PubertyChina
-
Camurus ABCompletedPhase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate CancerProstate CancerFinland, Hungary
-
Repros Therapeutics Inc.CompletedUterine LeiomyomataPoland
-
Colorado Center for Reproductive MedicineCompletedInfertility | EndometriosisUnited States
-
Fudan UniversityNot yet recruitingQuality of Life | Breast Cancer | Hormone Receptor-positive Breast CancerChina